Risk factors for the development of neuroleptic induced akathisia

By Miller C.H.   Hummer M.   Oberbauer H.   Kurzthaler I.   DeCol C.   Fleischhacker W.W.  

European Neuropsychopharmacology, Vol. 7, Iss. 1, 1997-02 ,pp. : 51-55

Elsevier

Access to resources Recommend Favorite

A beta-adrenoceptor antagonist, carteolol, in the treatment of neuroleptic-induced akathisia

By Aoba A.   Murasaki M.   Kamijima K.   Yagi G.   Komemushi S.   Miura S.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 391-391

Elsevier

Access to resources Recommend Favorite

Double-blind comparison of three fixed doses of sertraline and placebo in patients with panic disorder

By DuBoff E.   England D.   Ferguson J.M.   Londborg P.D.   Rosenthal M.H.   Smith W.   Wiese C.   Wolkow R.M.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 287-287

Elsevier

Access to resources Recommend Favorite

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol

By Andrezina Raisa   Josiassen Richard   Marcus Ronald   Oren Dan   Manos George   Stock Elyse   Carson William   Iwamoto Taro  

Psychopharmacology, Vol. 188, Iss. 3, 2006-10 ,pp. : 281-292

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Generalised Anxiety Disorder with Venlafaxine XR: A Randomised, Double-Blind Trial in Comparison with Buspirone and Placebo

By Rolland P.D.  

Clinical Drug Investigation, Vol. 19, Iss. 2, 2000-02 ,pp. : 163-165

Adis International

Access to resources Recommend Favorite